Testing effectiveness (Phase 2)Study completedNCT00946270What this trial is testingPomalidomide for Myelofibrosis PatientsWho this might be right forPolycythemia VeraThrombocythemia M.D. Anderson Cancer Center 70
Early research (Phase 1)Study completedNCT00910728What this trial is testingStudy to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis AstraZeneca 65
Not applicableStudy completedNCT02953704What this trial is testingMyelofibrosis and Essential Thrombocythemia Observational Study (MOST)Who this might be right forMPN (Myeloproliferative Neoplasms) Incyte Corporation 1,469
Early research (Phase 1)Active Not RecruitingNCT04041050What this trial is testingA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmWho this might be right forMyeloproliferative Neoplasm AbbVie 85
Large-scale testing (Phase 3)Study completedNCT01969838What this trial is testingMomelotinib Versus Ruxolitinib in Subjects With MyelofibrosisWho this might be right forPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis Sierra Oncology LLC - a GSK company 432
Testing effectiveness (Phase 2)UnknownNCT04640532What this trial is testingKRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFWho this might be right forMyelofibrosisPost-PV MFPost-ET Myelofibrosis+1 more Kartos Therapeutics, Inc. 116
Testing effectiveness (Phase 2)UnknownNCT04878003What this trial is testingStudy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) Kartos Therapeutics, Inc. 52
Testing effectiveness (Phase 2)Looking for participantsNCT05835466What this trial is testingReparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Who this might be right forMyelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF) Icahn School of Medicine at Mount Sinai 10
Early research (Phase 1)Ended earlyNCT01291784What this trial is testingAnti-TGF-beta Therapy in Patients With MyelofibrosisWho this might be right forMyelofibrosisPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more John Mascarenhas 3
Testing effectiveness (Phase 2)UnknownNCT01298934What this trial is testingLBH589 (Panobinostat) for the Treatment of MyelofibrosisWho this might be right forPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis Ronald Hoffman 22
Large-scale testing (Phase 3)UnknownNCT03662126What this trial is testingKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF) Kartos Therapeutics, Inc. 385
Large-scale testing (Phase 3)Ended earlyNCT03755518What this trial is testingA Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibWho this might be right forPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more Celgene 38
Not applicableStudy completedNCT01816256What this trial is testingScreening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative NeoplasmsWho this might be right forMyeloproliferative Neoplasms (MPN)Polycythemia Vera (PV)Essential Thrombocythemia (ET)+1 more University Health Network, Toronto 102
Not applicableActive Not RecruitingNCT06798805What this trial is testingUnraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative NeoplasmsWho this might be right forEssential Thrombocythemia (ET)Myelofibrosis (MF)Polycythemia Vera (PV) IRCCS Azienda Ospedaliero-Universitaria di Bologna 110
Early research (Phase 1)Looking for participantsNCT05025488What this trial is testingMutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmWho this might be right forMyelofibrosisEssential ThrombocythemiaMPN Marina Kremyanskaya 10
Large-scale testing (Phase 3)Study completedNCT03952039What this trial is testingAn Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibWho this might be right forPrimary MyelofibrosisPost-Polycythemia VeraMyelofibrosis Celgene 202
Testing effectiveness (Phase 2)Study completedNCT01644110What this trial is testingRuxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MFWho this might be right forPrimary MyelofibrosisSecondary MyelofibrosisPMF+3 more University of Ulm 96
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574What this trial is testingFlonoltinib Maleate Oral Regimens in Patients With MyelofibrosisWho this might be right forMyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more Chengdu Zenitar Biomedical Technology Co., Ltd 105
Early research (Phase 1)UnknownNCT05279001What this trial is testingA Safety and Tolerability Study of JaktinibWho this might be right forMyelofibrosis Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Testing effectiveness (Phase 2)Looking for participantsNCT05280509What this trial is testingStudy of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibWho this might be right forMyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more Telios Pharma, Inc. 70